Product Center
Received the clinical approval for a new drug of the first class of biological products
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-11-11
- Views:
(Summary description)In 2017, the company used its own patented technology to develop a new class of biological products: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA for clinical appro
Received the clinical approval for a new drug of the first class of biological products
(Summary description)In 2017, the company used its own patented technology to develop a new class of biological products: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA for clinical appro
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-11-11 10:57
- Views:
In 2017, the company used its own patented technology to develop a new class of biological products: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA for clinical approval.
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
